STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
brief summary
The purpose of this study is to compare the effects on participants' and liver cancer by adding a drug that is used on its own to treat this disease to a combination of two other drugs which is also used to treat liver cancer, compared to the two-drug combination alone.
detailed description
An earlier clinical trial showed that a single drug treatment for liver cancer helped stabilize or shrink participants' liver cancer and extend the time before their cancer got worse. A different clinical trial showed that a different two-drug combination helped extend how long participants with liver cancer lived after starting the treatment. Combinations of drugs that are similar to these treatments have been studied in a few people and seem promising, but it is not clear if the combination of all three drugs being used in this study can offer better results than standard treatment.
official title
A Phase II Study of STRIDE (Durvalumab + Tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC)